Drugs / ND-L02-s0201
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03241264 | Aug → Oct 2016 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02227459 | Oct 2014 → May 2016 | fibrotic liver disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01858935 | May 2013 → Feb 2014 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03538301 | Jun 2018 → Aug 2022 | idiopathic pulmonary fibrosis | Nitto Denko Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ND-L02-s0201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01858935 ↗ |
| Modality | Small interfering RNA (siRNA) | “a Vitamin A-Coupled Lipid Nanoparticle Containing siRNA Against HSP47” NCT01858935 ↗ |
| Route | Intravenous | “Single IV infusion.” NCT01858935 ↗ |